Purpose: To describe visual impairment (VI) over a 20-year period and its associations with age-related eye diseases and socioeconomic factors in the Beaver Dam Eye Study.
tion of Beaver Dam, Wisconsin, was performed from September 15, 1987 , through May 4, 1988 . Eligibility requirements for the study included living in the city or township of Beaver Dam and being 43 to 84 years of age at the time of the census. All persons eligible at the time of the census who were alive at follow-up were invited to participate at each examination, regardless of whether they had participated in a previous examination. No additional individuals outside of the group eligible for the study at the time of the census were invited to participate at follow-up examinations. There were 5924 eligible individuals, of whom 4926 participated in the baseline examination between March 1, 1988 , and September 15, 1990 Fig 1) . Ninety-nine percent of the cohort was white.
Approval was granted by the institutional review board at the University of Wisconsin. Written informed consent for the use and disclosure of protected health information was obtained from all subjects before being enrolled in the study and before each examination. The study was performed in accordance with the tenets of the Declaration of Helsinki.
The follow-up participation rate was high and similar for each examination. The main reason for nonparticipation was death ( Fig  1) . Unlike previous reports that describe the characteristics of participants and nonparticipants at a particular examination phase with those of patients who had previously participated (consistent with analyses in those articles), 9 -11 the participation information for each examination phase was accumulated into a single analysis, consistent with analyses reported in this article. Participation occurred at consecutive examinations for 10 429 of the 13 984 person-visits (75%) accumulated across all 4 examination intervals (3684 of 4926 participants at BDES1 returned for BDES2, 2783 of 3721 participants at BDES2 returned for BDES3, 2204 of 2962 participants at BDES3 returned for BDES4, and 1758 of 2375 participants at BDES4 returned for BDES5). The remaining 3555 person-visits were accumulated from 1660 person-visits (12%) in which a participant at one examination died before the next follow-up (445 BDES1 participants died before BDES2, 448 BDES2 participants died before BDES3, 358 BDES3 participants died before BDES4, and 409 BDES4 participants died before BDES5) and 1895 person-visits (13%) in which subjects participated at one examination but declined participation or only completed an interview at the next examination (797 BDES1 participants were alive and nonparticipants at BDES2, 490 BDES2 participants were alive and nonparticipants at BDES3, 400 BDES3 participants were alive and nonparticipants at BDES4, and 208 BDES4 participants were alive and nonparticipants at BDES5). Those who participated in the follow-up were more likely than nonparticipants who were alive or those who died before follow-up to be younger and, while adjusting for age, were more likely to have a higher annual household income, to have more education, not to be institutionalized, not to be visually impaired, not to have a central cataract, and not to have AMD (Table 1 , available at http://aaojournal.org). The mean and median times between the baseline and BDES5 examinations were 20.4 years (standard deviation, 0.59 year) and 20.3 years, respectively.
At each examination, the visual acuity (VA) from the betterseeing eye was used for analyses. Visits with unreliable (or unmeasured) VA in one of the eyes were not used for analyses. To be eligible for incidence analyses, a participant had to be seen at 2 consecutive visits and have reliable VA measured in both eyes at both visits. During each examination phase, at least 95% of participants had reliable VA in both eyes (Fig 1) . During BDES1, 4793 of the 4926 participants had reliable VA measurements. Of these 4793 persons, 1186 did not return for the BDES2 examination; 126 returned, but reliable VA measurements were not obtainable in at least 1 eye, leaving 3481 persons with reliable VA measurements in both eyes at both the BDES1 and BDES2 examinations. Similarly, 3569 of 3721 persons seen at BDES2 had reliable VA measurements in both eyes, among whom 2532 had reliable VA measurements in both eyes at BDES3. During BDES3, 2730 of 2962 persons had reliable VA measurements, among whom 2017 had reliable VA measurements at BDES4. During BDES4, 2230 of 2375 persons had reliable VA measurements, among whom 1618 had reliable VA at BDES5. Thus, over the 20 years of follow-up, there were a total of 9648 person-visits with reliable VA data available for change analyses.
Measurements
Similar procedures were used at all examinations. Participants underwent a standardized interview and examination at each visit. Information on demographic characteristics was obtained from a questionnaire. Street address was recorded for classification as a nursing home or group home. At baseline, this was almost exclusively nursing homes, but by BDES5, there were many residential communities that provided various levels of care, including some areas within these communities where residents were still completely independent. No distinction was made among areas within facilities, so persons were classified as institutionalized if any part of their living facility provided some level of care. Photographs of the ocular fundus 13 and the lens 14 were obtained after pharmacologic dilation of the pupil according to protocol and were graded in masked fashion by experienced graders. Slit-lamp photographs were obtained to grade the degree of nuclear sclerosis. Retroillumination photographs were obtained to grade presence and severity of cortical and posterior subcapsular cataracts. The protocols for photography and the grading procedures have been described previously. 15 Scores for nuclear sclerosis were based on comparisons with standard photographs, which resulted in a 5-step scale of severity based on degree of opacity of the nucleus. Scores for cortical and posterior subcapsular cataracts were based on estimated amount of involvement within grid segments. Central cataract was defined as presence of nuclear cataract (standard 3 or more) or 25% or more of the central circle of the grid with cortical or posterior subcapsular opacity present. History of cataract surgery was obtained by grading of red reflex photographs corroborated by clinical assessment during the slit lamp examination.
The Wisconsin Age-Related Maculopathy Grading System [15] [16] [17] was used to assess the presence and severity of lesions associated with AMD on the fundus photographs. Grading procedures, lesion descriptions, and detailed definitions for their presence and severity have been published elsewhere. 15 Early AMD was defined as the presence of soft drusen, any drusen with retinal pigmentary abnormalities (increased retinal pigment, retinal pigment epithelium depigmentation, or both), or both in the absence of signs of late AMD. Late AMD was defined as the presence of exudative macular degeneration, pure geographic atrophy, or both.
At all follow-up examinations, before refraction, participants were asked to read the Early Treatment Diabetic Retinopathy Study chart R modified for a 2-m distance with their current prescription without covering either eye. The number of letters read correctly was recorded. At all examinations, the refraction from a Humphrey 530 refractor (Carl Zeiss, Inc., Oberkochen, Germany) was placed in a trial lens frame and the best-corrected VA was remeasured for each eye by means of the Early Treatment Diabetic Retinopathy Study protocol with charts R1 and R2 mod- ified for a 2-m distance. 8, 18 If the best-corrected VA was 20/40 or worse in either eye, an Early Treatment Diabetic Retinopathy Study refraction was performed for that eye and the VA was measured. The interobserver difference among the examiners for the refraction or the best-corrected VA was low and not clinically appreciable (data not shown). Three levels of impairment in visual function were defined by the best-corrected VA in the betterseeing eye: no impairment (20/40 or better), any VI (worse than 20/40), and severe VI (legal blindness, 20/200 or worse).
Records of all persons with vision of 20/200 or worse in at least one eye were reviewed by the principal investigator (R.K.), and the primary cause of the severe VI was noted based on disease status ascertained from photographs and observations from the study examiners. When the cause was unclear, the participant's eye doctor was contacted.
Incidence of any VI was calculated within each 5-year interval between examinations. Persons with VA of 20/40 or better in one or both eyes at the beginning of a 5-year examination interval were considered at risk for incidence of any VI. Similarly, persons considered at risk for developing severe VI were those with VA better than 20/200 in one or both eyes at the beginning of a 5-year interval. For most analyses, age and other characteristics were defined at the beginning of an interval. Because all analyses used one VA measure (from the better-seeing eye) for a person, the corresponding AMD and central cataract statuses from this eye were used for analyses. When the VA was the same in both eyes, the AMD and central cataract statuses from the worse eye were used. For persons in which the AMD and central cataract statuses for the analysis eye were not gradable, if the VA in the other eye was similar (Ͻ10 letters different), the AMD and central cataract statuses from the other eye were used.
Statistical Analysis
Comparisons of participants and nonparticipants were performed using the main effect F test in a 2-way analysis of variance model and the Cochran-Mantel-Haenszel test of independence to adjust for age groups with continuous (e.g., education level attained) and categorical (e.g., VA) characteristics, respectively. Unless otherwise noted, all models include information from each 5-year interval with appropriate adjustments for correlation from multiple visits.
Risk factor information was updated at each examination. Model selection began with examination of the age relationship. After the appropriate age model was determined, age-period interactions were evaluated. Then, all other factors were considered separately, and interactions between the factor and age and period were evaluated. Statistically significant (PϽ0.05) univariate relationships were entered into a multivariate model. Cumulative incidence estimates were obtained from models with age and period alone. Backward selection was used to obtain a final parsimonious model. SAS software version 9 (SAS Inc, Cary, NC) was used for all analyses.
Results

Characteristics of the Cohort
Characteristics of the cohort participating at each examination are presented in Table 2 . The mean age increased from 62.0 years at BDES1 to 75.4 years at BDES5, with the proportion of those 85 years of age and older increasing from 1% at BDES1 to 15% at BDES5. The prevalence of central cataract and cataract surgery and the severity of AMD in right eyes (Table 2 ) and left eyes (data not shown) at the beginning of each interval increased over the 20-year period, as did the prevalence of more education, higher annual household income, and institutionalization.
Incidence of Visual Impairment
Incidence of VI was calculated among those without any impairment (in at least one eye) at the beginning of each interval. Visual impairment was present at the beginning of the interval in 42 of the 3481 persons with reliable VA measurements at both BDES1 and BDES2, in 21 of the 2532 persons with reliable VA measurements at both BDES2 and BDES3, in 18 of the 2017 persons with reliable VA measurements at both BDES3 and BDES4, and in 19 of the 1618 persons with reliable VA measurements at both BDES4 and BDES5. Thus, incidence of VI was evaluated in 9548 personvisits. Incidence of VI occurred in 38 of the 3439 persons at risk from BDES1 to BDES2, in 37 of the 2511 persons at risk from BDES2 to BDES3, in 28 of the 1999 persons at risk from BDES3 to BDES4, and in 28 of the 1599 persons at risk from BDES4 to BDES5. In total, VI developed over a 5-year period in 131 of 9548 (1.4%; 95% confidence interval [CI], 1.1%-1.6%) person-visits. Similarly, severe VI developed over a 5-year period in 34 of 9620 (0.4%; 95% CI, 0.2%-0.5%) person-visits.
Incidence of any VI over a 5-year period was associated linearly (log-odds in logistic models) with age and ranged from 0.1% in persons 50 to 54 years of age to 14.6% in persons 85 years of age and older. From the model, cumulative incidences of VI over 5, 10, 15, and 20 years starting at age 45 years with no impairment were computed (Table 3 , available at http://aaojournal.org). The estimated 20-year cumulative incidence varied from 0.6% in persons 50 years of age to 30.3% in persons 75 years of age with no impairment.
For specific age groups, the incidence of VI was slightly lower at more recent visits compared with earlier ones (Fig 2) . For example, at 65 to 69 years of age, the incidence of VI occurred in 0.6% of participants from BDES1 to BDES2 and in 0.5% of participants from BDES4 to BDES5; at 80 to 84 years of age, the incidence of VI occurred in 9.3% of participants from BDES1 to BDES2 and in 7.3% of participants from BDES4 to BDES5. There were no statistically significant interactions between period and age. Differences in incidence of VI from BDES1 to BDES2, BDES2 to BDES3, or BDES3 to BDES4 were not statistically significant after adjusting for age, but the incidence from BDES4 to BDES5 was statistically significantly lower (47% lower) than for BDES1 to BDES2 (odds ratio [OR] for last period vs. first period, 0.53; 95% CI, 0.32-0.87; P ϭ 0.01). The period effect was no longer significant after adjustment for other factors such as AMD (data not shown). Figure 3A -F (available at http://aaojournal.org) and Table 4 show the incidence of any VI and severe VI by age, sex, education level, income, institutionalization status, central cataract status, and AMD status at the beginning of an interval over the 20 years of the study. With just age and visit in the model, there were no associations (Table 5 ) with sex ( Fig 3A) , more education (Fig 3B) , higher income (Fig 3C) , or institutionalization (Fig 3F) . Persons in an institution had a different pattern of incidence of VI, but the numbers of institutionalized persons who were at risk for incidence (not visually impaired and returned for follow-up visit) were very low. Persons with late AMD (Fig 3E) were more likely to have incident VI than those without AMD or those with early AMD. There was no interaction of late AMD with age or visit. The relationship between cataract status (Fig 3D) and incident VI varied with age but was not statistically significant in personspecific models. The cataract relationship was more apparent when looking at each eye separately (data not shown).
Model building began with all significant factors from the univariate associations (Table 5) , which was just AMD. From this full model, nonsignificant terms were removed (visit was no longer statistically significant). With the new full model (age and AMD status), all other factors once again were evaluated, and income
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and institutionalization (including an interaction with age) became associated significantly with the incidence of VI. Both terms did not contribute independently, and income was a better predictor than institutionalization. Therefore, the final (most parsimonious) model contained age, income, and AMD severity level ( Table 5 ). The presence of early AMD (OR vs. none, 3.1) and late AMD (OR vs. none, 50) were statistically significantly associated with higher incidence of VI. For every income category, risk of incident VI was lower compared with persons with an annual income of $9000 or less. However, all the other income categories did not differ significantly from each other for the incidence of VI. None of the interactions tested were statistically significant.
Because AMD and central cataract may be evaluated better in eye-specific models, these were explored also. The eye-specific models also showed age, income, and AMD status to be associated with incident VI, but in addition, central cataract status and cataract-age interaction terms were significant (data not shown). At younger ages, persons with cataract were more likely to have incident VI, but at approximately 70 years of age or older, the incidence of VI was similar for persons with cataract when compared with persons without. The opposite was true for cataract surgery. At younger ages, persons with cataract surgery had a similar incidence of VI as persons without any cataract, but at older ages, persons with cataract surgery had a statistically significantly lower incidence of VI than persons without any cataract.
Incidence of Severe Visual Impairment
Incidence of severe VI was 0.35% overall (34 of 9620 personvisits) and varied with age, from 0.0% at 50 to 54 years of age to 0.0% at 60 to 64 years of age, 0.2% at 70 to 74 years of age, 1.6% at 80 to 84 years of age, and 6.9% at 85 years of age and older ( Table 4) . Only age and AMD were associated significantly with incidence of severe VI. In multivariate models, age was related linearly to incidence of severe VI, and AMD was associated with higher incidence of severe VI. With few events, models with institutionalization and cataract status failed to converge, and no interaction terms reached statistical significance. There was no period effect for severe VI (data not shown).
Visual Impairment in Persons 90 Years of Age and Older
One hundred one persons 90 years of age and older at BDES5 had reliable VA measurements in both eyes, of whom 27% (n ϭ 27) were visually impaired in their better eye, including 10 with severe VI. Similarly, 25% (3/12), 21% (13/63), and 23% (16/70) of persons 90 years of age and older at the time of BDES2, BDES3, and BDES4, respectively, had VI. Follow-up information for participants 90 years of age and older was limited because, on average, 64% of them died before the next visit and 44% of those who survived did not participate or did not have VA measured reliably in both eyes at follow-up. This loss to follow-up was higher for persons with VI. Furthermore, among the 29 persons 90 years of age or older during BDES2, BDES3, and BDES4 with VA measured at both visits, 10% already had VI. Among the 26 people 90 years of age or older without any VI, 31% (n ϭ 8) became visually impaired by followup.
Causes of Severe Visual Impairment
Of the 184 eyes with severe VI at their first visit and the 256 in which severe VI developed between visits, late AMD was the primary cause in 44% of eyes, branch or central retinal vein occlusion was the primary cause in 8%, and cataract was the primary cause in 10% (Table 6 ). The percentage of eyes with severe VI caused by AMD changed little over the 20 years of the study. Other less frequent causes of severe VI included macular hole (4%), diabetic retinopathy (3%), retinal detachment (3%), and trauma (8%). Some (e.g., trauma) were much more common causes of severe impairment at the first visit than of severe VI incident between visits, which diminished the apparent impact of other causes, for example, AMD. When eyes with severe VI caused by trauma, amblyopia, and congenital conditions were considered, AMD was the primary cause of severe VI in 30% of 184 eyes; however, when eyes with severe VI caused by trauma, amblyopia, and congenital conditions were removed from consideration, AMD was the primary cause of severe VI in 43% of 128 eyes among persons first seen with impairment.
Correctable Visual Impairment by New Refraction
In 19.3% (n ϭ 1986) of person-visits, there was an improvement of 5 letters or more read after refraction compared with their current refraction. Among the 406 visits in which persons were visually impaired with their current correction, 26% (n ϭ 104) of persons improved by at least 1 line but were still impaired, and 38% (n ϭ 153) of persons improved by at least 1 line and were no longer impaired after refraction. The percentage of persons with VI correctable by new refraction changed little over the 20 years of the study. Among persons with impairment with their current prescription, improvement of 1 line of vision or more on refraction that resulted in VA of 20/40 or better was 73% less common in those institutionalized (OR, 0.27; PϽ0.001) and 90% less common in those who had late AMD in either eye (OR, 0.10; PϽ0.001). With institutionalization and AMD present, there were no differences with age. There were no differences by examination phase, education, income, sex, or cataract status.
Discussion
The incidence of VI over a 5-year period increased with age in the BDES, reaching 15% in persons 85 years of age and older. There was an age-period effect in VI in the population that was no longer significant after adjusting for AMD status. Age-related macular degeneration remained the most important cause of severe VI. The prevalence of VI correctable by new refraction remained unchanged throughout the 20 years of the study.
There was a small decrease in the odds of incident VI from the beginning of this study to the end (OR for incidence between BDES4 to BDES5 vs. BDES1 to BDES2, 0.53; 95% CI, 0.32-0.87). Although this was no longer statistically significant after adjustment for AMD, it still suggests lower rates of incidence in the last 5 years of the study. This may be in part the result of new treatment interventions for AMD. 7 To our knowledge, there are no other population-based studies that have examined and reported changes in the incidence of VI over a 20-year period. The National Health Interview Survey, based on self-reported responses to 2 questions about vision, showed a nonsignificant annual downward trend of Ϫ0.04% per year from 1997 through 2005. 2 In those data, there were statistically significant downward trends in self-reported VI in those who reported being seen by an eye care provider in the previous 12 months (Ϫ0.18% per year), in those with diabetes (Ϫ0.81% per year), and in persons 80 years of age and older (Ϫ0.46% per year). Lee et al 2 speculated that these downward trends may be the result of improvements in the treatment of ocular disease, increased eye care use in those with VI, or both.
Although the decline in incidence of impairment is not statistically significant after adjustment for AMD, the suggestion of a period effect may have public health implica- tions. If a decline in the incidence of VI is occurring in the United States population, it would result in lower estimates than those expected based on the 2004 prevalence report. 19 In the BDES, 13.3% of persons 75 years of age or older had VI and 2.4% had severe VI over a 10-year period using information collected from the 1988 through 1990 interval to the 1998 through 2000 interval, with corresponding incidence during the last 10-year period of 9.9% and 2.7%, respectively. Projecting these estimates to the current United States population 75 years of age and older (n ϭ 18 766 000) results in 26% fewer persons demonstrating VI over the next 5 years using the current estimates (n ϭ 1 851 355) compared with the older estimates (n ϭ 2 502 134). However, it is possible that selective survival and participation and uncontrolled confounding may explain these changes in incidence of VI over time. At every visit, those with VI or AMD were less likely to participate, and nonparticipation of those at risk rather than a true decline in VI over the course of the study partly may explain the decrease in the incidence of VI in the more recent period.
In the BDES, the 20-year cumulative incidence of any VI and severe VI for persons 60 years of age without prior impairment was 3.0% and 0.3%, respectively, and for persons 70 years of age without prior impairment, it was 14.8% and 2.7%, respectively. If the BDES estimates are extrapolated to the future, then approximately 3% of people 60 years of age (with a current average life expectancy of 21 more years for men and 24 for women) are at risk of VI developing over their remaining lifetime. 20 There are no similar long-term, population-based incidence data from the United States and there are limited data from elsewhere with which to compare these estimates. For example, in a study in Italy, severe VI developed over a 12-year period in 0.7% of those 40 years of age and older at baseline. 3 In the Barbados Eye Study, the 9-year cumulative incidence in persons 40 to 84 years of age at baseline for any VI was 10.1%, and for severe VI it was 2.1%. 1 These differences among studies may reflect varied prevalence in the distribution of age-related ocular diseases by race. In addition, there may be different environmental factors at the various study sites. It is also possible that there has been a temporal decrease in VI in current times when the BDES was examined, compared with when the older studies were done.
This report used the expected 5-year incidence to calculate the 20-year cumulative incidence. Although it is possible to calculate directly the incidence with life-table approaches to the observed data, the direct approach over long follow-up, with loss to follow-up among the oldest ages, limits the stability of 20-year incidence estimates. For example, to calculate directly the 20-year cumulative incidence for a 75-year-old, enough people 75 years of age are required at the baseline examination to return for all examinations (and still be at risk for incidence). In the BDES, as in other studies, there are usually a small number of persons in this group. Instead, data were used from persons 75, 80, 85, and 90 years of age at BDES1 along with the persons 75, 80, 85, and 90 years of age at the time of BDES2, BDES3, and BDES4 to identify the 5-year incidence. Then, the life-table approaches with those estimates were used to calculate the expected 20-year cumulative incidence. Because these 5-year incidences were estimated with more data, the calculated 20-year incidences provide a more precise estimate than what could be obtained directly. If the 10-, 15-and 20-year cumulative incidence is calculated directly for any impairment in a 60-year-old, then 1.4%, 1.6%, and 2.5%, respectively, are observed, whereas the expected cumulative incidence from the present models predicts 0.5%, 1.2%, and 3.0% for the 10-, 15-, and 20-year cumulative incidence, respectively.
Age-related macular degeneration remained the leading cause of severe VI in the BDES, affecting a similar proportion of eyes throughout the 20 years. Retinal vein occlusion was a more frequent cause of severe VI than diabetic retinopathy. This is consistent with the decrease in proliferative diabetic retinopathy and macular edema reported in persons with type 2 diabetes through better glycemic control and timely detection, as well as treatment of proliferative retinopathy and clinically significant macular edema with laser photocoagulation. 5 Retinal vein occlusions and other conditions (e.g., ischemic optic neuropathy), although less frequent in the population than proliferative retinopathy and clinically significant macular edema, are more likely to affect vision because there are no prevention programs and limited treatment strategies to restore vision. Other conditions, for example, trauma and amblyopia, which account for 9% and 3% of severe VI, respectively, are infrequent causes of incident severe VI in persons 40 years of age or older; approaches to prevent and treat them must be focused on persons in the early years of life when these conditions occur. 
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Visual impairment that can be corrected by refraction has been estimated cross-sectionally to involve approximately 25% to 50% of those with VI in population-based studies. 11, [21] [22] [23] [24] [25] Over the 20 years of the BDES, 38% of eyes with VI were correctable by new refraction. It is important to correct VI because it has been shown to affect self-rated quality of life and to be associated with a higher frequency of falls than in persons without VI. 23 In the BDES, while adjusting for age, having AMD and not being institutionalized were associated with having correctable VI (compared with those with no improvement in VI). In the Blue Mountains Eye Study, older age and, after adjusting for age, being married, home ownership, high job prestige, having more than a high school education, and being a current driver were factors associated with being less likely to have correctable VI. 26 In the BDES, frequency of correctable VI varied little over the 20-year period. This was similar to the lack of variation in correctable VI in the Blue Mountains Eye Study, in which approximately 68% of those visually impaired had correctable VI. Similar sociodemographic measures were associated with correctable VI in both studies.
In the BDES, only higher income was associated with less VI after adjustment for age and AMD status. This was reported previously and in part may be the result of having better access to care and information and better overall health. [27] [28] [29] However, the effect of income on VI was small. With just AMD and age in the model, institutionalization also was associated with incident VI but did not remain in the model after income was also added. Income and institutionalization are highly correlated, so each can be significant, but not independently. The model with income was reported because it had a better overall fit than the model with institutionalization. Institutionalization also was associated with less VI correctable by new refraction. This may be the result of a lowered likelihood of surgically indicated interventions for treatable conditions, for example, cataract surgery for central cataract in persons institutionalized because of higher frequency of cognitive dysfunction and other comorbidities or the lack of access to ophthalmologic care.
Although this study has many strengths, there are limitations that may affect its outcomes and generalizability. First, selective survival may have affected the findings. Second, as people age into their tenth decade of life, measuring vision reliably becomes more difficult because of cognitive decline and comorbidities.
In summary, these data provide unique information regarding changes in VI over a period of significant change in medical and ophthalmologic care. They show a relatively high long-term incidence of VI (21%) and severe VI (7%) in persons 85 years of age and older. There were significant age-period effects explained, in part, by AMD. This has important public health care implications in estimating the projected burden of the number of those in the United States population expected to become visually impaired. Continued national epidemiologic surveillance is needed to monitor changes in the incidence and prevalence of VI and the diseases that cause them to estimate the costs and benefits of new ophthalmologic interventions after they are introduced. 
